Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Escitalopram in Cell Assay Workflows
2026-09-26
This scenario-driven guide explains how Escitalopram (SKU B1183) can be used thoughtfully in serotonergic cell research, from stock preparation to assay interpretation. It separates transporter evidence from cytotoxicity outcomes and connects laboratory findings to clinical evidence without overstating what either can establish.
-
Fluoxetine HCl Beyond Serotonin-First Models
2026-09-25
Fluoxetine HCl is a useful serotonergic probe—but its value in translational neuroscience depends on asking what the experiment can and cannot establish. Developmental SSRI findings point to persistent, motivation-selective changes involving nucleus accumbens mu-opioid receptors, making a case for separating drug target engagement from circuit-level outcomes.
-
Amitriptyline HCl: Practical Research Workflow
2026-09-25
Amitriptyline HCl (SKU B2231) provides a documented small-molecule perturbation for receptor and signaling studies, with product-specified potency, solubility, and storage information to guide setup. Use it in controlled neuropharmacology experiments, not as a selective probe or standalone evidence of disease-model efficacy without orthogonal validation.
-
6-OHDA Hydrochloride: A Model-Design Guide
2026-09-24
Explore how 6-OHDA hydrochloride creates catecholaminergic injury models and how to interpret its effects without confusing cellular uptake with functional outcomes. This guide also draws a careful assay-design lesson from research on nanoparticle protein coronas.
-
SAR131675 VEGFR-3 Inhibitor: Applied Workflows
2026-09-24
Use SAR131675 to probe VEGFR-3-dependent endothelial signaling with nanomolar biochemical and cell-based readouts, while separating receptor-specific effects from broader angiogenic phenotypes. This workflow emphasizes dose selection, formulation checks, and careful interpretation of a separate nicotine–kidney disease review used as a model for endpoint design—not evidence of a kidney indication.
-
Adefovir Workflows for HBV and OAT1 Research
2026-09-23
Build reproducible Adefovir experiments around two distinct strengths: HBV polymerase inhibition and OAT1 substrate behavior. A case report of phosphate-wasting bone disease adds a practical reminder to pair antiviral work with renal and mineral-metabolism questions when those are within scope.
-
CBD, Orofacial Pain, and Affective Circuitry
2026-09-23
A 2026 Brain Research Bulletin study shows that cannabidiol (CBD) reduces both inflammatory orofacial nociception and pain-associated affective deficits in mice through coordinated peripheral endocannabinoid, central pain-network, and serotonergic mechanisms. Its integrated behavioral, biochemical, and fiber-photometry design provides a useful framework for studying pain as a sensory, emotional, and cognitive disorder rather than as an isolated reflex.
-
Neuromedin S (rat): Practical GPCR Assay Guide
2026-09-22
Neuromedin S (rat), SKU B5466, provides a defined peptide agonist for controlled studies of neuromedin U receptor signaling and GPCR/G protein signaling. This guide covers preparation, assay controls, and stability handling; the reagent is for scientific research workflows only and should not be used for diagnostic, therapeutic, or medical purposes.
-
Amikacin Sulfate: Targeting NTM Granulomas
2026-09-22
Amikacin Sulfate is more than a bactericidal aminoglycoside: it is a platform for asking how antibiotic exposure can be concentrated where Mycobacterium avium persists. This article connects ribosomal mechanism, dendritic-cell delivery, experimental controls, and translational decision-making for researchers developing more precise NTM therapies.
-
Escitalopram Workflows for Serotonergic Research
2026-09-21
Build reproducible Escitalopram assays around transporter selectivity, vehicle control, and phenotype-aware analysis. This workflow connects 5-HT reuptake inhibition with practical antidepressant research and the anxious-depression findings reported in a controlled augmentation study.
-
VEGFC–Macrophage Signaling in NASH Fibrosis
2026-09-21
This study identifies a hepatocyte-derived VEGFC–VEGFR-3–CCL2/CCR2 axis that promotes inflammatory macrophage recruitment and limits macrophage phenotypic resolution during high-fat diet-induced hepatic fibrosis. Pharmacological VEGFR-3 inhibition, hepatocyte-specific Vegfc deletion, human clinical data, and cell-based experiments together position VEGFC suppression as a mechanistic component of naringin-mediated protection.
-
Targeted Amikacin Delivery into Mycobacterial Granulomas
2026-09-20
Montes-Worboys and colleagues developed a dendritic-cell carrier system to direct fluorescently traceable amikacin into Mycobacterium avium granulomas in infected mice. The study provides proof of localization and supports cell-mediated delivery as a strategy for increasing antibiotic exposure at infected tissue, while stopping short of demonstrating superior therapeutic efficacy.
-
Amitriptyline HCl in Neuropharmacology Workflows
2026-09-19
Amitriptyline HCl provides a practical multi-receptor perturbation tool for receptor signaling, blood-brain barrier, and neuropharmacology assays. This guide combines concentration planning, fresh-solution handling, and lipidomics-inspired controls to improve mechanistic interpretation without overstating evidence from unrelated disease models.
-
Amikacin Sulfate: Reliable Cell Assays
2026-09-18
This scenario-driven guide shows how Amikacin Sulfate (SKU C8696) can support more interpretable viability, proliferation, and intracellular killing experiments. It connects concentration selection, host-cell compatibility, CFU endpoints, storage, and supplier evaluation to published amikacin data.
-
Adefovir (GS-0393): From Mechanism to Translation
2026-09-18
A translational perspective on Adefovir (GS-0393) that connects HBV DNA polymerase inhibition with OAT1-mediated renal pharmacokinetics, experimental design, and reproducible research workflows.